Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
Cerevel Therapeutics Holdings, Inc. (CERE)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
10/12/2023
8-K
Quarterly results
10/12/2023
424B5
Form 424B5 - Prospectus [Rule 424(b)(5)]:
10/11/2023
8-K
Quarterly results
10/11/2023
424B5
Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/02/2023
10-Q
Quarterly Report for the period ended June 30, 2023
08/02/2023
8-K
Quarterly results
07/11/2023
144
Form 144 - Report of proposed sale of securities:
06/08/2023
8-K
Submission of Matters to a Vote of Security Holders Interactive Data
06/01/2023
144
Form 144 - Report of proposed sale of securities:
05/19/2023
10-K/A
Annual Report for the period ended December 31, 2022 [amend]
05/10/2023
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
"
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
"
05/08/2023
144/A
Form 144/A - Report of proposed sale of securities: [Amend]
05/08/2023
144
Form 144 - Report of proposed sale of securities:
05/05/2023
144
Form 144 - Report of proposed sale of securities:
05/04/2023
144
Form 144 - Report of proposed sale of securities:
05/04/2023
144
Form 144 - Report of proposed sale of securities:
05/03/2023
8-K
Quarterly results
04/28/2023
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023
SC 13D/A
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/21/2023
SC 13D
Form SC 13D - General statement of acquisition of beneficial ownership:
02/22/2023
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans:
02/22/2023
10-K
Annual Report for the period ended December 31, 2022
02/22/2023
8-K
Quarterly results
02/14/2023
5
DEKKERS MARIJN E (Director) has filed a Form 5 on Cerevel Therapeutics Holdings, Inc.
02/14/2023
5
Sulzberger Gabrielle (Director) has filed a Form 5 on Cerevel Therapeutics Holdings, Inc.
02/09/2023
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023
8-K
Other Events, Financial Statements and Exhibits Interactive Data
Docs:
"
Investor Contact:
"
12/19/2022
8-K
Quarterly results
11/21/2022
EFFECT
Form EFFECT - Notice of Effectiveness:
11/08/2022
S-3
Form S-3 - Registration statement under Securities Act of 1933:
11/08/2022
10-Q
Quarterly Report for the period ended September 30, 2022
11/08/2022
8-K
Quarterly results
Docs:
"
Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with schizophrenia Received FDA Fast Track designation for emraclidine in Alzheimer’s disease psychosis; Phase 1 trial in healthy, elderly volunteers to be initiated by year-end Cash, cash equivalents and marketable securities of $1,030 million as of September 30, 2022, expected to support operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., November 8, 2022 –
"
08/18/2022
SC 13D/A
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/16/2022
8-K
Quarterly results
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy